Forum: Financial Investment Forum. - Discuss Stocks, Cryptocurrency, And Other Financial Investments

Thread: Read if you want one stock you can retire on

Page 5 of 7 FirstFirst 1234567 LastLast
  1. #101  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Got em on the nie dip at $4 this morning as expected. Works for me...
    Reply With Quote  
     

  2. #102  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568
    Recommendation in Wall Street's Best Investments
    Prior Dick Davis Digest
    featured PRED in the May 15th publication issue 817 page 12-13
    the recommendation was from www.saadvisory.com
    www.saadvisory.com see April 22 and 29 2019 email alert
    We remain extremely bullish as the flow of pressers continue to create stronger and stronger building blocks for this potential blockbuster

    Sure PRED is not going straight up, but don't get left at the train station.
    We have NASDAQ listing (already baked in)
    2.assume brokerage alignment rapidly after confirmation of listing
    3.institution participation
    4. partnerships, acquisitions, joint ventures
    5.endometriosis test kits
    6. OA trial and ready for FDA Introduction
    7.Plus many other things that are going surface
    Reply With Quote  
     

  3. #103  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    707
    Do you have a price target for this Bruce or are you just letting this ride for a while?
    Reply With Quote  
     

  4. #104  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Quote Originally Posted by RapStar View Post
    Do you have a price target for this Bruce or are you just letting this ride for a while?
    From almost 9 months ago ($1.16 p/s)...

    My 12 month target is 10

    My long term target is 100 ( 3-5 years )
    Reply With Quote  
     

  5. #105  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    707
    Quote Originally Posted by MattyMatt View Post
    From almost 9 months ago ($1.16 p/s)...

    My 12 month target is 10

    My long term target is 100 ( 3-5 years )
    Thanks Matty Matt
    Reply With Quote  
     

  6. #106  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Quote Originally Posted by RapStar View Post
    Thanks Matty Matt
    No problem. I'm right there with him...Started buying at $1.19, bought a good bit at $.88, loaded up again at $2, and have been buying the dips ever since. $1.60ish average on all shares, and I don't plan to sell any for quite some time...Will consider unloading a little to ride freebies at $15+, but if/when we get to $5, DD price could come fairly quick....

    Continued success to us. Enjoy the ride...
    Reply With Quote  
     

  7. #107  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    707
    Quote Originally Posted by MattyMatt View Post
    No problem. I'm right there with him...Started buying at $1.19, bought a good bit at $.88, loaded up again at $2, and have been buying the dips ever since. $1.60ish average on all shares, and I don't plan to sell any for quite some time...Will consider unloading a little to ride freebies at $15+, but if/when we get to $5, DD price could come fairly quick....

    Continued success to us. Enjoy the ride...
    Awesome. Looking like some great buys there! Wish I saw this thread earlier, but I'm in a few times in the 3's so zero complaints. Good luck to all, I'll be around here more often now given this.
    Reply With Quote  
     

  8. #108  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568
    Reply With Quote  
     

  9. #109  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568


    Predictive Technology Group Reports Third Quarter Fiscal 2019 Financial Results

    Nine-month revenue increased 217% to $30 million with $3.1 million in positive cash flow from operations

    Email Print Friendly Share
    May 21, 2019 09:00 ET | Source: Predictive Technology Group, Inc.


    SALT LAKE CITY, May 21, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED) (the Company), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, reports financial results for the three and nine months ended March 31, 2019 and provides a business update.
    Management Commentary
    “I’m pleased to report our 10th consecutive quarter of sequential growth in revenue. Third quarter fiscal 2019 revenue of $11.3 million was up 167% over the third quarter of fiscal 2018,” said Bradley Robinson, CEO of Predictive Technology Group. “Revenue for the first nine months of fiscal 2019 exceeded $30 million, up 217% over the year-ago period, and we generated $3.1 million in cash flow from operations.
    “We have made exceptional progress in building a strong infrastructure to support the development and commercialization of our proprietary genetic-based diagnostics and therapeutics,” he added. “Predictive Biotech is now operating in our recently opened, state-of-the-art production laboratory and R&D facility that was expanded to meet the production and sales needs of our human cell and tissue products for use in cellular therapies and regenerative medicine. We also finalized the integration of Taueret Laboratories and Inception Dx into Predictive Laboratories, providing us with a CAP/CLIA-accredited laboratory for processing our genetic-based tests. We strengthened our Board with the appointment of independent directors with exceptional industry, public affairs, financial and governance experience. More recently we submitted an application to list Predictive common stock for trading on the NASDAQ, a move that we believe will generate increased visibility and credibility for our Company.”
    Third Quarter and Recent Highlights
    Corporate Developments

    • Integrated the sales and marketing team from FlagshipHealth Group, previously a consultant contractor, to support commercial activities for Predictive Biotech and Predictive Laboratories through combined domestic direct sales and a nationwide distributor network.
    • Named Sen. Orrin G. Hatch, Ronald Barhorst and Jay M. Moyes to its Board of Directors, expanding its Board to six including four independent directors.
    • Submitted an application to list its common stock to trade on the NASDAQ.

    Predictive Laboratories

    • Completed the acquisition of Taueret Laboratories, LLC, a provider of genetic testing and DNA analysis services through its CAP/CLIA-certified laboratory, to provide for faster entry into the high-growth women’s health testing market with proprietary commercial products.
    • Integrated over $5 million of recently purchased new genomics equipment and supplies into laboratory to expand the technical capabilities and capacities.
    • Appointed Christine Seward, MS, CGC as Senior Vice President of Sales and Marketing of Predictive Laboratories, bringing extensive experience commercializing molecular diagnostics including products in the reproductive space from her 16 years at Myriad Genetics.
    • Announced former Taueret Laboratories Chief Operations Officer Lesa Nelson and Director of Quality Control Debbie Dyckman joined Predictive Laboratories.
    • Launched ARTguide™ genetic test for reproductive endocrinologists into 14 Key Opinion Leader (KOL) clinics to refine the test ordering and reporting processes.
    • Presented a poster titled The Genetic Architecture of Endometriosis at the Society for Reproductive Investigation (SRI) meeting, demonstrating the ability of the proprietary genetic test ENDORisk™ to segregate patients with endometriosis from those without in the Caucasian population with a high degree of sensitivity (Area Under the ROC Curve = 0.91). The mean genetic risk score for endometriosis was 1.6 in the general population versus 5.3 in endometriosis patients, determined to be statistically significant with a p-value of less than 0.001.

    Predictive Biotech

    • Reported 10th consecutive quarter-over-quarter revenue growth.
    • Completed buildout of a new 2,000-square-foot production laboratory and R&D facility meeting good manufacturing Practice (GMP) and Good Tissue Practice (GTP) requirements for Predictive Biotech. The lab features an ISO 7 cleanroom and 18 ISO 5 production hoods.

    Third Quarter Fiscal 2019 Results
    Revenue for the third quarter of fiscal 2019 was $11.3 million, an increase of 167% from $4.2 million for the third quarter of fiscal 2018. The increase was due to continued growth in the sales volume and increasing demand for human cell and tissue products.
    Gross profit margin for the third quarter of fiscal 2019 was 57.7%, compared with 57.6% for the prior-year period.
    Sales, marketing and administrative (SG&A) expenses for the third quarter of fiscal 2019 were $7.9 million, compared with $5.7 million for the prior-year quarter. The increase was primarily due to higher headcount in accounting, marketing, administrative support and other functions necessary to support growth.
    Research and development (R&D) expenses for the third quarter of fiscal 2019 were $1.5 million, compared with $367,000 a year ago, with the increase primarily driven by higher spending to develop improved processing methods for the Company’s human cell and tissue products, as well as continued development of diagnostic products.
    Amortization and depreciation expenses for the third quarter of fiscal 2019 were $2.4 million, compared with $1.1 million for the prior-year period, with the increase primarily due to an increase in the intangible asset portfolio arising from the business combinations and asset acquisition.
    The net loss attributable to controlling interest for the third quarter of fiscal 2019 was $3.7 million, or $0.01 per share, compared with a net loss attributable to controlling interest for the third quarter of fiscal 2018 of $3.2 million, or $0.01 per share.
    Year-to-date Financial Results
    Revenue for the first nine months of fiscal 2019 was $30.0 million, a 217% increase from $9.5 million for the first nine months of fiscal 2018. Gross profit margin for first nine months of fiscal 2019 was 63.8%, an improvement from 62.5% from the prior-year period.
    SG&A expenses for the nine months ended March 31, 2019 were $19.1 million, compared with $14.7 million for the nine months ended March 31, 2018, with the increase due to higher headcount in sales and general and administrative functions as the Company continues to expand, as well as increasing public company compliance costs.
    R&D expenses for the first nine months of fiscal 2019 were $3.8 million, compared with $417,000 for the prior-year period, with the increase due to costs related to internal development of existing products, and an increased focus in developing DNA diagnostics and new methods for processing tissues.
    Depreciation and amortization expenses for the nine months ended March 31, 2019 were $6.1 million, compared with $3.4 million for the prior-year period, with the increase primarily due to a laboratory buildout and related laboratory equipment purchases, computer hardware and software purchases, and intangible assets arising from acquisitions.
    Other expense, net for the nine months ended March 31, 2019 was $832,000, compared with other income, net of $178,000 for the prior-year period. The change was primarily driven by increased losses from equity method investment caused by increasing ownership in Juneau Biosciences, LLC, partially offset by the bargain purchase gain arising from the acquisition of Taueret Laboratories, LLC.
    The net loss attributable to controlling interest for the first nine months of fiscal 2019 was $8.0 million, or $0.03 per share, versus a net loss attributable to controlling interest for the first nine months of fiscal 2018 of $7.5 million, or $0.03 per share.
    Cash and cash equivalents as of March 31, 2019 were $1.8 million, compared with $1.2 million as of June 30, 2018. Cash provided by operating activities for or the nine months ended March 31, 2019 was $3.1 million, a $5.7 million improvement from cash used in operating activities of $2.6 million for the nine months ended March 31, 2018.
    Revisions of Previously Issued Financial Statements: During the financial close for the third fiscal quarter of 2019 the Company discovered errors in the Company’s accounting for income taxes, primarily with regard to impact of income taxes on the Company’s accounting for business combinations and asset acquisitions. The errors were determined to be material to the Company’s consolidated balance sheets, consolidated statements of operations, consolidated statement of stockholders’ equity, and statements of cash flows for the years ended June 30, 2018 and June 30, 2017. The financial information for prior periods has been restated to reflect these adjustments.
    About Predictive Biotech, Inc.
    Predictive Biotech, Inc., a Salt Lake City life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
    About Predictive Laboratories, Inc.
    Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). In 2018 this group launched its novel test for women experiencing infertility, called ARTGuide™, to select beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns. The test is expected to change the way that advanced reproductive technologies such as in vitro fertilization (IVF) are used to assist couples having difficulty conceiving a pregnancy.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
    Forward-Looking Statements
    This release contains “forward-looking” statements that are based on present circumstances and on Predictive Technology Group’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements and any statements of the plans and objectives of management for future operations and forecasts of future growth and value, are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. Such forward-looking statements are made only as of the date of this release and Predictive Technology Group assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. The information in this press release should be read in conjunction with, and is modified in its entirety by, the Registration Statement on Form 10 (the “Form 10”) filed by the Predictive Technology Group with the Securities and Exchange Commission (the “SEC”) and all of the Company’s other public filings with the SEC (the “Public Filings”). In particular, the financial information contained herein is subject to and qualified by reference to the financial statements contained in the Form 10 and Public Filings, the footnotes thereto and the limitations set forth therein. Investors may not rely on the press release without reference to the Form 10 and the Public Filings.
    Contact:
    Investors
    LHA Investor Relations
    Jody Cain jcain@lhai.com
    Kevin Mc Cabe kmccabe@lhai.com
    310-691-7100
    Reply With Quote  
     

  10. #110  
    RX Member
    Join Date
    Dec 2007
    Location
    Los angeles
    Posts
    77
    Most impressive pick.
    I wonder how long till they get off the pinks?
    Reply With Quote  
     

  11. #111  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Quote Originally Posted by Bozzie View Post
    Most impressive pick.
    I wonder how long till they get off the pinks?
    1-2 weeks is a good guess as we're in Day 19 of their proposal to uplist, which is said to take 4-6 weeks. Barring no hiccups, I don't see why it doesn't happen...
    Reply With Quote  
     

  12. #112  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568
    Incase anyone is curious . ( I added @3.60, will add more tomorrow)


    PRED action is nothing shocking - it broke out at 3.87, pushed up to 4.75 and then pulled back to the 61.8% / 50% retrace. If it tagged $3 and then bounced that would still be bullish








    Reply With Quote  
     

  13. #113  
    Their undisputed masterpiece is "Hip to be Square." The Falls's Avatar
    Join Date
    Dec 2005
    Location
    Dallas
    Posts
    5,190
    If you are up big, I would sell now and wait for the immediate dip coming....I just bought in earlier in the 3.60s...initial position
    Reply With Quote  
     

  14. #114  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Quote Originally Posted by The Falls View Post
    If you are up big, I would sell now and wait for the immediate dip coming....I just bought in earlier in the 3.60s...initial position
    I’m just adding again at $3.50. Hope I get to do it again, today...
    Reply With Quote  
     

  15. #115  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Actually, maybe I will sell some here and hope to scoop up some at $3 or a little under. This one should see $5+ within a month, so this current decline doesn’t bother me in the least bit...
    Reply With Quote  
     

  16. #116  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    707
    Quote Originally Posted by MattyMatt View Post
    Actually, maybe I will sell some here and hope to scoop up some at $3 or a little under. This one should see $5+ within a month, so this current decline doesn’t bother me in the least bit...
    Will be eyeing some buys today as well.
    Reply With Quote  
     

  17. #117  
    RX Member
    Join Date
    Dec 2007
    Location
    Los angeles
    Posts
    77
    Is the billion dollar market cap a concern to anyone?
    Seems like taking a little profit could be worth something but the company looks super solid for the long run.

    Great call
    Reply With Quote  
     

  18. #118  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Scooped up a couple more 1k at $3.28 this morning. Works for me and tapped out currently. Let's ride...
    Reply With Quote  
     

  19. #119  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568
    Griping Stocks: Predictive Technology Group Inc (OTC US:PRED)

    By
    David Holmes -

    May 23, 20190
    83





    On 22-05-2019 (Wednesday), the shares-rate of the Company Predictive Technology Group Inc, PRED exchange OTC US, is an exciting player in the Medical.
    Analyst Summary Of The Predictive Technology Group IncIn Stock Exchange OTC US:
    ThePredictive Technology Group Inc (OTC US: PRED) opened the business at 3.51 and closed at 3.43 with the change of -0.09 during the period of last trading session.
    Trading Gap-Up & Gap-Down with Prices (High & Low):
    The current high trading price remained at Predictive Technology Group Inc while previous high price was 4.17 and current low trading price remained Predictive Technology Group Inc while previous low price was 3.41 at which stock traded during the course of the day. It is mandatory for investors to know the trading comparison of current & last day sessions. The Gap-Up -0.66 is the difference between the current session’s open and the previous session’s High and Gap-up percentage became -0.16% Similarly, the Gap-Down $0.1 is the difference between the current session’s open and the previous session’s Low and Gap-down percentage became 0.03%.
    Volume Indicator:
    Trading volume can help an investor to identify the momentum in a stock and confirm a trend. If trading volume increases, prices generally moves in the same direction. That is, if a security is continuing higher in an uptrend, the volume of the security should also increase and vice versa. The Company’s current volume remained at 570700 with the percent of 0.37%. It will also better to share yesterday’s volume of the company i.e.; 614900.
    Market Capitalization:
    Market Capitalization is the true measure of a company’s value. There’s a common mis-conception that a company’s per-share stock price holds as much importance as its market capitalization when it comes to choosing stocks to purchase. This fallacy occurs especially often in the case of new investors. The market Capitalization of the company recorded at 959323000.
    Highest & Lowest Prices Of OTC US,Predictive Technology Group Inc With Moving Average:
    A high/low is the highest and lowest price at which a stock has traded during the previous week (05-days). It is a technical indicator used by buyer / seller and investors who view the previous week high or low as an important aspect in determining a stock’s current value and predicting future price movement. The highest price over the last 05 days was remained at 4.6 with the high parentage of -0.25. The Lowest price over the last 05 days was remained at 3.18with the low percentage of 0.08.
    A Moving Average (MA) is a comprehensively indicator and is based on past price.
    05 Days Moving Average (MA): 3.93%
    20 Days Moving Average (MA) & Signals: 3.3177%
    50 Days Moving Average (MA) & Signals: 2.6578%
    Weighted Alpha:
    Weighted Alpha alert that stock has increased or decreased over an one-year period with a higher weighting for recent price activity. The company’s Predictive Technology Group Inc has a Weighted Aplha 38.60.
    Return on Equity (ROE)%:
    ROE is considered a measure of how effectively management is using a company’s assets to create profits. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. The company Predictive Technology Group Inc having 0%.
    PE (TTM):
    TTM stands for Trailing Twelve Months. It is being used to represent the performance of Predictive Technology Group Inc. The Price/Earnings Ratio is often referred to as P/E (ttm), which is calculated as the stock’s current price divided by a company’s trailing 12-month Earnings per Share (EPS). The PE(ttm) of the Company recorded at 0%.
    · Forward PE Ratio
    A company with a higher forward P/E ratio than the industry or market average indicates an expectation the company is likely to experience a significant amount of growth. If a company’s stock fails to meet the high ratio value with increased per share earnings, the price of the stock will fall. The forward P/E ratio of Predictive Technology Group Inc, OTC US recorded as 0.00%.


    https://nysenewsanalyst.com/2019/05/...nc-otc-uspred/
    Reply With Quote  
     

  20. #120  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568
    PRED featured again HB target 6.5 https://www.thetechtrader.com/charts...m_campaign=COD
    Reply With Quote  
     

  21. #121  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568


    Predictive Technology Group Names Industry Veteran Dr. Douglas Rabin Vice President of Medical Affairs, Women’s Health of Predictive Laboratories

    Appointment expands Predictive Laboratories’ management team to support goal of bringing innovative molecular diagnostics to market

    Email Print Friendly Share
    June 04, 2019 09:00 ET | Source: Predictive Technology Group, Inc.


    SALT LAKE CITY, June 04, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health. In this newly created position, he will provide critical medical affairs support for the women's health clinical franchise. Dr. Rabin has more than 25 years of experience in women's healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.
    Dr. Rabin previously served as Medical Director for Women’s Health at Quest Diagnostics, where he successfully completed a seminal paper in cervical cancer screening, initiated a trial in BRCA population testing and helped launch Quest’s non-invasive prenatal and Jewish genetic diagnostics. He also was instrumental in the expansion of the women’s health franchise at Quest through the acquisition of Reprosource, Inc. He previously was a National Health Service Corps (NHSC) physician, and a National Scholarship Awardee at the National Institutes of Health (NIH) and its gynecological consultant, as well as a consultant to multiple Big Four accounting firms. His clinical credentials include management of a successful in vitro fertilization (IVF) practice for more than 10 years and as a full-time obstetrician and gynecologist. In addition, Dr. Rabin served as the medical director for a pharmaceutical company addressing women's health issues.
    Dr. Rabin earned a bachelor's degree in economics from Harvard College and a medical degree from the Temple University School of Medicine. He completed his Ob/Gyn training at the Hospital of the University of Pennsylvania and spent eight years at the NIH after completing a fellowship in endocrinology and infertility at Mt Sinai School of Medicine.
    Dr. Rabin said, “I am extremely excited to join Predictive Technology Group. I view our diagnostics to identify patients with endometriosis as novel predictive approaches in managing fertility, pelvic pain and improving women’s lives.”
    “We welcome Dr. Rabin to the Predictive team to support our goal of commercializing our innovative, genetic-based diagnostics that are initially focus on human infertility and women’s health,” said Bradley Robinson, CEO of Predictive Technology Group. “Dr. Rabin is highly accomplished in launching pharmaceutical and diagnostic products at Fortune 500 companies. His experience and commitment to delivering improved, more comprehensive healthcare to patients will be of tremendous assistance in supporting our mission of employing advanced molecular diagnostics to prevent or eliminate disease for generations to come.”
    About Predictive Laboratories, Inc.
    Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). Its novel test for women experiencing infertility, ARTGuide™, was launched in late 2018 to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as IVF, are used to assist couples having difficulty conceiving a pregnancy.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
    Forward-Looking Statements
    To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
    Contact:
    Investors
    LHA Investor Relations
    Jody Cain jcain@lhai.com
    Kevin Mc Cabe kmccabe@lhai.com
    310-691-7100

    Reply With Quote  
     

  22. #122  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    707
    Great close today! $4.84!!!
    Reply With Quote  
     

  23. #123  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,568
    HARRY BOXER PRED FEATURED 6.5-6.75 TARGET https://www.thetechtrader.com/charts...906042395.html
    Reply With Quote  
     

  24. #124  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    707
    Quote Originally Posted by brucefan View Post
    HARRY BOXER PRED FEATURED 6.5-6.75 TARGET https://www.thetechtrader.com/charts...906042395.html
    Reply With Quote  
     

  25. #125  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,932
    Quote Originally Posted by MattyMatt View Post
    Actually, maybe I will sell some here and hope to scoop up some at $3 or a little under. This one should see $5+ within a month, so this current decline doesn’t bother me in the least bit...
    Took it 2 weeks...lol Ready, BOOM!

    Those extra few thousand I picked up avg $3.28 are already sitting pretty just as expected...
    Reply With Quote  
     

Posting Permissions
  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •